Emerging therapies and their delivery for treating age-related macular degeneration

Chloe N Thomas, Dawn A Sim, Wen Hwa Lee, Nada Alfahad, Andrew D Dick, Alastair Denniston, Lisa J Hill

Research output: Contribution to journalArticlepeer-review

62 Downloads (Pure)

Abstract

Age-related macular degeneration (AMD) is the most common cause of blindness in the Western world and is characterised in its latter stages by retinal cell death and neovascularisation and earlier stages with the loss of parainflammatory homeostasis. Patients with neovascular AMD (nAMD) are treated with frequent intraocular injections of anti-vascular endothelial growth factor (VEGF) therapies, which are not only unpopular with patients, but carry risks of sight-threatening complications. A minority of patients are unresponsive with no alternative treatment available and some patients who respond initially eventually develop a tolerance to treatment. New therapeutics with improved delivery methods and sustainability of clinical effects are required, in particular for non-neovascular AMD (90% of cases and no current approved treatments). There are age-related and disease-related changes that occur which can affect ocular drug delivery. Here, we review the latest emerging therapies for AMD, their delivery routes, and implications for translating to clinical practice.

Original languageEnglish
JournalBritish Journal of Pharmacology
Early online date26 Mar 2021
DOIs
Publication statusE-pub ahead of print - 26 Mar 2021

Keywords

  • age-related macular degeneration
  • anti-VEGF
  • complement
  • drug delivery
  • immunotherapy
  • ocular disease
  • retina

ASJC Scopus subject areas

  • Pharmacology

Fingerprint

Dive into the research topics of 'Emerging therapies and their delivery for treating age-related macular degeneration'. Together they form a unique fingerprint.

Cite this